You are here: Home: LCU 1 | 2007: Chandra P Belani, MD: Select publications

SELECT PUBLICATIONS

Bedano PM et al. Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. Proc ASCO 2006;Abstract 7043.

Douillard J et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Presentation. ASCO 2005;Abstract 7013.

Fehrenbacher L et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Proc ASCO 2006;Abstract 7062.

Pepe C et al. Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. Proc ASCO 2006;Abstract 7009.

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial  E4599. Proc ASCO 2005;Abstract 4.

Strauss GM et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update on Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc ASCO 2006; Abstract 7007.

Winton T et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2589-97. Abstract

Table of Contents

Top of Page